As we navigate the complexities of aging, concerns about cardiovascular health, maintaining healthy blood pressure, and preventing adverse thrombotic events often come to the forefront. Many individuals, proactively seeking to support their well-being, explore natural interventions that might complement conventional medical approaches. This often leads to a crucial question: how do various natural compounds, particularly nattokinase, compare in their mechanisms and evidence base for supporting cardiovascular health?
Understanding the nuances and scientific backing for each option is vital, especially when considering supplements that interact with the body’s intricate clotting mechanisms. This article aims to provide an evidence-based comparison of nattokinase against other commonly discussed natural alternatives, helping you make informed decisions in consultation with your healthcare provider.
FTC Disclosure: NattokinaseHub may earn a commission from qualifying purchases made through affiliate links in this article. This helps support our research and content creation.
Nattokinase: A Fibrinolytic Powerhouse
Nattokinase is a serine protease enzyme isolated from natto, a traditional Japanese fermented soybean food. Its primary mechanism of action is its direct fibrinolytic activity, meaning it can directly break down fibrin, a key protein component of blood clots. This enzymatic action is distinct from many other natural compounds.
Beyond direct fibrinolysis, lab and animal studies suggest nattokinase may enhance the body’s natural fibrinolytic system [3][4] by increasing the production of tissue plasminogen activator (t-PA) and urokinase-type plasminogen activator (u-PA), and by inhibiting plasminogen activator inhibitor-1 (PAI-1). These lab findings underlie its reputation as a blood clot prevention agent, but the reputation outruns the human evidence: the longest randomized trial found no slowing of carotid artery thickening [5].
Evidence for Nattokinase
An uncontrolled study in 15 healthy volunteers found fibrinogen, factor VII and factor VIII fell by 9%, 14% and 17% over 2 months, but with no control group it cannot show nattokinase was the cause [6][7]. The pooled human evidence is narrower than it is usually made to sound. The only systematic review and meta-analysis of nattokinase randomized controlled trials pooled six studies covering 546 participants and found reductions of roughly 3.4 mmHg systolic and 2.3 mmHg diastolic against placebo[1]. The most-cited North American trial enrolled 79 adults with elevated readings (74 completed), gave 100 mg per day for eight weeks, and saw diastolic pressure fall from 87 to 84 mmHg while the systolic result did not differ from placebo, an effect that was clearest in men [2]. Those are real but small shifts, measured on surrogate markers rather than on heart attacks or strokes.
The longest trial found no benefit even on those markers. In 265 healthy adults followed for a median of 3 years, nattokinase did not slow carotid artery thickening and had no significant effect on blood pressure [5].
Another area of research focuses on its potential role in deep vein thrombosis (DVT) and arterial thrombosis. While promising, larger, long-term randomized controlled trials are needed to definitively establish its efficacy in primary and secondary prevention of thrombotic events. Safety remains paramount; individuals on anticoagulant or antiplatelet therapy must consult their physician before considering nattokinase due to the risk of increased bleeding.
Nattokinase vs. Omega-3 Fatty Acids (EPA/DHA)
Omega-3 fatty acids, specifically eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), are widely recognized for their broad cardiovascular benefits. These essential fatty acids, primarily found in fatty fish, influence platelet aggregation, reduce inflammation, and support endothelial function.
Research note: No clinical studies directly comparing newer oral anticoagulants (NOACs) with nattokinase exist, so nattokinase cannot be claimed to match them [11].
Mechanisms and Evidence
Unlike nattokinase’s direct fibrinolytic action, omega-3s primarily exert their effects by reducing platelet aggregation, making platelets less “sticky.” They also contribute to blood pressure support by improving vascular elasticity and reducing systemic inflammation. Large-scale trials, such as the REDUCE-IT study, have shown that high-dose EPA can significantly reduce major adverse cardiovascular events in high-risk patients.
However, omega-3s do not directly break down existing fibrin clots. Their role is more preventative in reducing the propensity for clot formation and supporting overall vascular health. The risk of bleeding with standard doses of omega-3s is generally low but can increase with very high doses or when combined with other anticoagulant medications.
Large omega-3 trials do not all agree. In the STRENGTH trial a high-dose omega-3 formulation did not beat corn oil on the primary cardiovascular endpoint (12.0% versus 12.2%), and a Cochrane review found little or no effect of fish oil on all-cause mortality while triglycerides fell by about 15% [8][9].
Nattokinase vs. Serrapeptase
Serrapeptase is another proteolytic enzyme, derived from the silkworm intestine bacterium, Serratia marcescens. Like nattokinase, it is often promoted for its anti-inflammatory and fibrinolytic properties, leading to frequent comparisons.
Mechanisms and Evidence
Serrapeptase is believed to break down non-living tissue, including fibrin, and reduce inflammation by inhibiting the release of bradykinin. While it shares some enzymatic characteristics with nattokinase, its specific fibrinolytic potency and direct impact on established blood clots in human cardiovascular systems are less extensively studied than nattokinase.
Clinical evidence for serrapeptase in cardiovascular applications, particularly for blood clot prevention or blood pressure support, is considerably weaker and less consistent than for nattokinase. Most studies on serrapeptase focus on its anti-inflammatory effects in conditions like sinusitis or post-operative swelling. Caution regarding bleeding risk is also advised, especially when combined with other blood-thinning agents.
Nattokinase vs. Garlic Extract (Aged Garlic Extract)
Garlic, particularly aged garlic extract (AGE), has a long history in traditional medicine for cardiovascular health. Its active compounds, such as S-allyl cysteine, are thought to contribute to its beneficial effects.
Mechanisms and Evidence
Aged garlic extract influences multiple pathways relevant to cardiovascular health. It can help lower blood pressure by promoting vasodilation, reduce cholesterol levels, and inhibit platelet aggregation. Meta-analyses have supported AGE’s ability to modestly lower both systolic and diastolic blood pressure, comparable to some pharmaceutical interventions in magnitude.
While garlic can reduce platelet stickiness, it does not possess the direct fibrinolytic enzyme activity seen with nattokinase. Its action is more focused on preventing clot formation through antiplatelet effects and supporting overall vascular integrity. The risk of bleeding with garlic supplements is generally low but should be considered, especially before surgery or with concurrent anticoagulant use.
Comparative Overview of Natural Cardiovascular Support Supplements
To summarize the distinctions, the table below outlines the primary mechanisms and key evidence areas for each discussed supplement. This allows for a quick comparison of their unique strengths.
| Supplement | Primary Mechanism | Key Cardiovascular Benefits | Evidence Strength (for CV effects) | Bleeding Risk (with caution) |
|---|---|---|---|---|
| Nattokinase | Direct fibrinolysis; enhances endogenous fibrinolysis | Blood clot prevention; blood pressure support | Moderate (promising, smaller human trials) | Moderate to High (especially with anticoagulants) |
| Omega-3 Fatty Acids | Reduces platelet aggregation; anti-inflammatory; improves endothelial function | Reduced CVD events (high risk); blood pressure support; triglyceride reduction | Mixed (large trials disagree) [8][9] | Low to Moderate (high doses or with anticoagulants) |
| Serrapeptase | Proteolytic enzyme; anti-inflammatory | Limited direct CV evidence; mostly anti-inflammatory | Low (very limited for CV applications) | Moderate (less studied for CV, potential with anticoagulants) |
| Aged Garlic Extract | Antiplatelet; vasodilation; cholesterol modulation | Blood pressure support; cholesterol reduction; anti-inflammatory | Moderate to High (consistent, meta-analyses) | Low to Moderate (especially with anticoagulants or before surgery) |
Integrating Nattokinase into Your Health Strategy
Nattokinase stands out due to its unique direct fibrinolytic properties, making it a distinct option for individuals interested in blood clot prevention and blood pressure support. While other natural compounds offer valuable cardiovascular benefits, their mechanisms often differ significantly.
For those considering nattokinase, it is crucial to recognize its potential interactions, particularly with prescription anticoagulants (e.g., warfarin, direct oral anticoagulants like apixaban or rivaroxaban) and antiplatelet drugs (e.g., aspirin, clopidogrel). Combining nattokinase with these medications can significantly increase the risk of bleeding or bruising.
Always engage in a thorough discussion with your primary care physician or cardiologist before initiating any new supplement, especially if you have pre-existing cardiovascular conditions, are on medication, or are preparing for surgery. Your physician can assess your individual risk factors and help integrate supplements safely into your overall health plan.
Finding Quality Nattokinase Supplements
When searching for nattokinase, prioritize products from reputable manufacturers that provide clear labeling of Nattokinase Units (FUs), indicating enzymatic activity. Look for supplements that have undergone third-party testing for purity and potency, ensuring you are receiving the stated dosage.
Consider forms such as nattokinase capsules for convenient dosing or nattokinase powder if you prefer to mix it. Always check the ingredient list for unnecessary fillers or allergens. For specific needs, you might explore vegetarian nattokinase options.
Frequently Asked Questions (FAQ)
What is the recommended dosage for nattokinase?
The most-cited trial dose is 100 mg (2,000 FU) per day, but daily doses across the trials pooled in a 2023 meta-analysis ranged from 1,200 to 8,000 FU [2][1]. However, optimal dosing can vary based on individual needs and health goals. Always follow product label instructions and consult a healthcare professional for personalized advice.
Can nattokinase replace prescription blood thinners?
No, nattokinase should never replace prescription blood thinners without direct medical supervision. Its effects are not as predictable or potent as pharmaceutical anticoagulants, and stopping prescribed medication can lead to serious health risks.
How long does it take for nattokinase to work?
In a small crossover trial in 12 healthy young men, a single dose raised the clot-breakdown marker D-dimer at 6 and 8 hours, though all changes stayed within the normal range [10]. However, noticeable changes in blood pressure or long-term benefits typically require consistent supplementation over several weeks to months. Individual results may vary.
Are there any side effects of nattokinase?
The most significant side effect is an increased risk of bleeding, especially when combined with other blood-thinning agents. Other reported side effects are generally mild and may include gastrointestinal upset or allergic reactions in sensitive individuals.
Is nattokinase safe for long-term use?
While many individuals use nattokinase long-term, comprehensive long-term safety studies, particularly in large populations, are still emerging. Regular medical check-ups and discussions with your doctor are advised to monitor your health and assess continued suitability.
Who should avoid nattokinase?
Individuals with bleeding disorders, those on anticoagulant or antiplatelet medications, those undergoing surgery, or pregnant/breastfeeding women should avoid nattokinase unless specifically advised and monitored by a healthcare professional.
These statements have not been evaluated by the FDA. This product is not intended to diagnose, treat, cure, or prevent any disease.
References
- Li X, Long J, Gao Q, et al. Nattokinase Supplementation and Cardiovascular Risk Factors: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Rev Cardiovasc Med. 2023;24(8):234. PMID 39076715
- Jensen GS, Lenninger M, Ero MP, Benson KF. Consumption of nattokinase is associated with reduced blood pressure and von Willebrand factor, a cardiovascular risk marker: results from a randomized, double-blind, placebo-controlled, multicenter North American clinical trial. Integr Blood Press Control. 2016;9:95-104. PMID 27785095
- Tetsumei Urano et al. The Profibrinolytic Enzyme Subtilisin NAT Purified fromBacillus subtilis Cleaves and Inactivates Plasminogen Activator Inhibitor Type 1. Journal of Biological Chemistry (2001). PMID 11325965
- Hiroyuki Sumi et al. Natto Bacillus as an Oral Fibrinolytic Agent: Nattokinase Activity and the Ingestion Effect of Bacillus subtilis natto. Food Science and Technology Research (2004). doi:10.3136/fstr.10.17
- Hodis HN et al. Nattokinase atherothrombotic prevention study: A randomized controlled trial. Clinical hemorheology and microcirculation (2021). PMID 33843667
- European Food Safety Authority (EFSA NDA Panel) Safety of fermented soybean extract NSK-SD as a novel food pursuant to Regulation (EC) No 258/97. European Food Safety Authority (EFSA NDA Panel) (2016). source
- Weng Y et al. Nattokinase: An Oral Antithrombotic Agent for the Prevention of Cardiovascular Disease. International journal of molecular sciences (2017). PMID 28264497
- Abdelhamid AS et al. Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease. The Cochrane database of systematic reviews (2020). PMID 32114706
- Nicholls SJ et al. Effect of High-Dose Omega-3 Fatty Acids vs Corn Oil on Major Adverse Cardiovascular Events in Patients at High Cardiovascular Risk: The STRENGTH Randomized Clinical Trial. JAMA (2020). PMID 33190147
- Yuko Kurosawa et al. A single-dose of oral nattokinase potentiates thrombolysis and anti-coagulation profiles. Scientific Reports (2015). PMID 26109079
- Muric M et al. Comparative Cardioprotective Effectiveness: NOACs vs. Nattokinase-Bridging Basic Research to Clinical Findings. Biomolecules (2024). PMID 39199344
These statements have not been evaluated by the Food and Drug Administration. This information is not intended to diagnose, treat, cure, or prevent any disease. Content is for informational purposes only and is not medical advice; consult a qualified healthcare provider before starting any supplement. As an Amazon Associate we earn from qualifying purchases.
